erythropoietin

(redirected from Erythropoietins)
Also found in: Thesaurus, Medical, Encyclopedia.
Related to Erythropoietins: Hemopoietin, erythropoietin stimulating factor

e·ryth·ro·poi·e·tin

 (ĭ-rĭth′rō-poi-ē′tĭn)
n.
1. A glycoprotein hormone that stimulates the production of red blood cells by stem cells in bone marrow. Produced mainly by the kidneys, it is released in response to decreased levels of oxygen in body tissue.
2. Epoetin alfa.

[erythropoiet(ic) + -in.]

erythropoietin

(ɪˌrɪθrəʊpɔɪˈiːtɪn)
n
(Biochemistry) a hormone, secreted by the kidney in response to low levels of oxygen in the tissues, that increases the rate of erythropoiesis. It has been used as a performance-enhancing drug for athletes and racehorses. Abbreviation: EPO

e•ryth•ro•poi•e•tin

(ɪˌrɪθ roʊˈpɔɪ ɪ tn, -pɔɪˈit n)

n.
a hormone that stimulates production of red blood cells and hemoglobin in the bone marrow.
[1945–50]
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.erythropoietin - a glycoprotein secreted by the kidneys that stimulates the production of red blood cells
glycoprotein - a conjugated protein having a carbohydrate component
Translations
EpoetinErythropoetinErythropoietinHämatopoetin
eritropoietina

e·ryth·ro·poi·e·tin

[MIM*133170]
n. eritropoyetina, proteína no dializable que estimula la producción de eritrocitos.

erythropoietin

n eritropoyetina
References in periodicals archive ?
Deposits and Guarantees required: Lot 1 long-acting erythropoietins in nephrology bail (5% of the contract, the contract documents).
This capacity of erythropoietin to increase oxygenation (and thereby enhance physical performance and stamina) has led to its abuse by athletes; accordingly, recombinant human erythropoietins (rHuEPO) are among the substances classified as "doping agents" and are prohibited by the World Anti-Doping Agency and other sports organizations (Jelkmann, 2009).
In contrast, similar recombinant erythropoietins sold in the United States have been linked with rates that are about 50-fold lower.
This product, known as Epoetin Omega, has physicochemical characteristics that are distinctly different from other erythropoietins or Epos (alpha and beta) currently on the market worldwide.
Comparative study of N-linked oligosaccharides of urinary and recombinant erythropoietins.
Study Reliability And Reporting Limitations I-1 Disclaimers I-2 Data Interpretation & Reporting Level I-2 Quantitative Techniques & Analytics I-3 Product Definitions And Scope Of Study I-3 Blood Growth Factors I-3 Erythropoietins I-4 Colony Stimulating Factors I-4 Interferons I-4 Interleukins I-4 Tissue Growth Factors I-4
Recombinant erythropoietins have been used successfully for more than a decade for treating the anemia associated with CKD.
Review of drugs in the treatment of dialysis side effects including: erythropoietins, IV iron, vitamin D and phosphate lowering drugs
Aranesp has a unique pharmacokinetic profile compared to conventional rHu-EPO molecules, which means it can be administered less frequently than other erythropoietins.
Erythropoietins with a market size of over US$9 billion and rising, Monoclonal Antibodies with a market size approaching US$7 billion and a stratospheric growth rate, Human Insulins, Interferons and Colony Stimulating Factors are some of the main biopharmaceutical classes profiled in this report.
Erythropoietin (EPO) is a complex molecule, first isolated in 1977 (1) and now well-known for its physiological role in the regulation of red blood cell production in the bone marrow.